Publicaciones (25) Publicaciones de María Quindós Varela

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

  3. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  4. SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2771-2782

2023

  1. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study

    Melanoma research, Vol. 33, Núm. 5, pp. 388-397

  2. Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

    International Journal of Molecular Sciences, Vol. 24, Núm. 13

  3. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

  4. Study of Ferroptosis Transmission by Small Extracellular Vesicles in Epithelial Ovarian Cancer Cells

    Antioxidants, Vol. 12, Núm. 1

  5. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study

    Cancers, Vol. 15, Núm. 11

2022

  1. Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus

    Clinical and Translational Oncology, Vol. 24, Núm. 8, pp. 1515-1523

  2. SEOM-GEICO clinical guidelines on endometrial cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 625-634

2020

  1. Differential characteristics of HMGB2 versus HMGB1 and their perspectives in ovary and prostate cancer

    Current Medicinal Chemistry, Vol. 27, Núm. 20, pp. 3271-3289

  2. The HMGB1-2 ovarian cancer interactome. The role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response

    Cancers, Vol. 12, Núm. 9, pp. 1-22

  3. The challenges and opportunities of lncRNAs in ovarian cancer research and clinical use

    Cancers, Vol. 12, Núm. 4

2019

  1. Characterization of HMGB1/2 interactome in prostate cancer by yeast two hybrid approach: Potential pathobiological implications

    Cancers, Vol. 11, Núm. 11

2015

  1. Trombosis venosa de localización atípica en pacientes con cáncer

    Medicina Clinica, Vol. 144, Núm. S1, pp. 38-40

2014

  1. Angiosarcoma irresecable tratado con bevacizumab y paclitaxel

    Actas Dermo-Sifiliograficas

  2. MicroARN circulantes en sangre de pacientes con cáncer de próstata

    Actas Urologicas Espanolas, Vol. 38, Núm. 10, pp. 633-639

2013

  1. Importancia de los distintos tipos histológicos en el CPNCP

    Revisiones en Cancer

2010

  1. Evaluation of Plakophilin-3 mRNA as a biomarker for detection of circulating tumor cells in gastrointestinal cancer patients

    Cancer Epidemiology Biomarkers and Prevention, Vol. 19, Núm. 6, pp. 1432-1440